CN103536973A - 一种聚乙烯醇磁性微粒及其制备方法和用途 - Google Patents
一种聚乙烯醇磁性微粒及其制备方法和用途 Download PDFInfo
- Publication number
- CN103536973A CN103536973A CN201310513211.0A CN201310513211A CN103536973A CN 103536973 A CN103536973 A CN 103536973A CN 201310513211 A CN201310513211 A CN 201310513211A CN 103536973 A CN103536973 A CN 103536973A
- Authority
- CN
- China
- Prior art keywords
- polyvinyl alcohol
- magnetic
- solution
- microgranule
- magnetic particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004372 Polyvinyl alcohol Substances 0.000 title claims abstract description 214
- 229920002451 polyvinyl alcohol Polymers 0.000 title claims abstract description 214
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 54
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 15
- -1 hydrogen ions Chemical class 0.000 claims abstract description 12
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 207
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 207
- 239000004005 microsphere Substances 0.000 claims description 89
- 238000003756 stirring Methods 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 35
- 239000004531 microgranule Substances 0.000 claims description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 238000005406 washing Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 11
- 239000003431 cross linking reagent Substances 0.000 claims description 11
- 235000002639 sodium chloride Nutrition 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000376 reactant Substances 0.000 claims description 10
- 238000000015 thermotherapy Methods 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 8
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 8
- 230000010102 embolization Effects 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 229960003787 sorafenib Drugs 0.000 claims description 8
- 238000002626 targeted therapy Methods 0.000 claims description 8
- 206010002091 Anaesthesia Diseases 0.000 claims description 7
- 230000037005 anaesthesia Effects 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000001117 sulphuric acid Substances 0.000 claims description 6
- 235000011149 sulphuric acid Nutrition 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 claims description 5
- 229940043276 diisopropanolamine Drugs 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 150000001299 aldehydes Chemical class 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 238000001949 anaesthesia Methods 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 229960001680 ibuprofen Drugs 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 229940102253 isopropanolamine Drugs 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 claims description 4
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002584 gefitinib Drugs 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 3
- 229950000578 vatalanib Drugs 0.000 claims description 3
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 2
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 2
- GHSCYMOJHVOGDJ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-hydroxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1O GHSCYMOJHVOGDJ-UHFFFAOYSA-N 0.000 claims description 2
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 229930195573 Amycin Natural products 0.000 claims description 2
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052693 Europium Inorganic materials 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 229910052689 Holmium Inorganic materials 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 2
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004100 Oxytetracycline Substances 0.000 claims description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
- 229930192786 Sisomicin Natural products 0.000 claims description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 2
- 229910052771 Terbium Inorganic materials 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 229910052775 Thulium Inorganic materials 0.000 claims description 2
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 238000006136 alcoholysis reaction Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 2
- 229960003644 aztreonam Drugs 0.000 claims description 2
- 229960001192 bekanamycin Drugs 0.000 claims description 2
- 108700004675 bleomycetin Proteins 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 claims description 2
- 229910021538 borax Inorganic materials 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 229960003150 bupivacaine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960002727 cefotaxime sodium Drugs 0.000 claims description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- 229940097572 chloromycetin Drugs 0.000 claims description 2
- 229960002023 chloroprocaine Drugs 0.000 claims description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960001747 cinchocaine Drugs 0.000 claims description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960003324 clavulanic acid Drugs 0.000 claims description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960002398 demeclocycline Drugs 0.000 claims description 2
- 229960003807 dibekacin Drugs 0.000 claims description 2
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000616 diflunisal Drugs 0.000 claims description 2
- 229950010160 dimethocaine Drugs 0.000 claims description 2
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960000385 dyclonine Drugs 0.000 claims description 2
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims description 2
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 229960001419 fenoprofen Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 229960003704 framycetin Drugs 0.000 claims description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 2
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 229950000998 hydroxyprocaine Drugs 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 229960000798 isepamicin Drugs 0.000 claims description 2
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- 229930182824 kanamycin B Natural products 0.000 claims description 2
- SKKLOUVUUNMCJE-FQSMHNGLSA-N kanamycin B Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SKKLOUVUUNMCJE-FQSMHNGLSA-N 0.000 claims description 2
- SKKLOUVUUNMCJE-UHFFFAOYSA-N kanendomycin Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)C(O)C(CO)O2)O)C(N)CC1N SKKLOUVUUNMCJE-UHFFFAOYSA-N 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229960005287 lincomycin Drugs 0.000 claims description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 2
- 229940072082 magnesium salicylate Drugs 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229960002409 mepivacaine Drugs 0.000 claims description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 2
- 229960004270 nabumetone Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052756 noble gas Inorganic materials 0.000 claims description 2
- 229960003994 oxacillin sodium Drugs 0.000 claims description 2
- 229960000625 oxytetracycline Drugs 0.000 claims description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
- 235000019366 oxytetracycline Nutrition 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 229960003899 parethoxycaine Drugs 0.000 claims description 2
- OWWVHQUOYSPNNE-UHFFFAOYSA-N parethoxycaine Chemical compound CCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 OWWVHQUOYSPNNE-UHFFFAOYSA-N 0.000 claims description 2
- 229960001914 paromomycin Drugs 0.000 claims description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 claims description 2
- 229950007049 phenacaine Drugs 0.000 claims description 2
- 229960002895 phenylbutazone Drugs 0.000 claims description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 229960001807 prilocaine Drugs 0.000 claims description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960005038 quinisocaine Drugs 0.000 claims description 2
- 229960003485 ribostamycin Drugs 0.000 claims description 2
- 229930190553 ribostamycin Natural products 0.000 claims description 2
- NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 claims description 2
- NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001549 ropivacaine Drugs 0.000 claims description 2
- 229960005224 roxithromycin Drugs 0.000 claims description 2
- 229960000953 salsalate Drugs 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 229960005456 sisomicin Drugs 0.000 claims description 2
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
- 229960004025 sodium salicylate Drugs 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000004328 sodium tetraborate Substances 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229960005256 sulbactam Drugs 0.000 claims description 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 2
- 229960000894 sulindac Drugs 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- 229940034785 sutent Drugs 0.000 claims description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002372 tetracaine Drugs 0.000 claims description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229960000707 tobramycin Drugs 0.000 claims description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
- 229960001017 tolmetin Drugs 0.000 claims description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 2
- 229950002569 trimecaine Drugs 0.000 claims description 2
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims description 2
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 claims description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 abstract description 12
- 239000000696 magnetic material Substances 0.000 abstract description 7
- 239000003377 acid catalyst Substances 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 65
- 239000011859 microparticle Substances 0.000 description 28
- 238000002595 magnetic resonance imaging Methods 0.000 description 24
- 208000005189 Embolism Diseases 0.000 description 19
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- 208000001435 Thromboembolism Diseases 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 11
- 229910001447 ferric ion Inorganic materials 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 6
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229910001448 ferrous ion Inorganic materials 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005672 electromagnetic field Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 238000007171 acid catalysis Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005575 aldol reaction Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000011553 magnetic fluid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- PRXRUNOAOLTIEF-WUOFIQDXSA-N sorbitan trioleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C\CCCCCCCC)C1OCC(O)C1OC(=O)CCCCCCC\C=C\CCCCCCCC PRXRUNOAOLTIEF-WUOFIQDXSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种聚乙烯醇磁性微粒及其制备方法和用途,该聚乙烯醇磁性微粒通过使聚乙烯醇微粒、磁性金属离子及碱性物质反应制成。本发明的聚乙烯醇磁性微粒在制备过程中能够避免磁性材料与酸性催化剂中的氢离子发生反应,从而提高了聚乙烯醇磁性微粒的磁响应性及分散性。
Description
技术领域
本发明属于医药制剂领域,涉及一种聚乙烯醇磁性微粒的制备方法和用途。
背景技术
磁性微球是指含有无机磁性材料的微球。磁性微球不仅具有普通微球的特性,还具有在磁场下快速磁响应的特性,能在外加磁场的作用下被定位和导向。目前,磁性微球已广泛用于环境监测、生物学和医学等诸多领域,在医学领域中磁性微球可用于栓塞、热疗、磁靶向性治疗和细胞分离等方面。
聚乙烯醇是一种合成的高分子化合物,具有合成方便、生物相容性好、价格便宜及使用方便等优点。以聚乙烯醇为原料合成的聚乙烯醇颗粒栓塞剂已在临床上应用了三十余年,广泛用于各种栓塞治疗中。聚乙烯醇还用于制备止血纤维、人工皮肤、避孕药膜、代血浆及眼药膜等,也可以作为药物缓释载体材料制备微球。
基于聚乙烯醇制备的磁性微球在栓塞、热疗和磁靶向性治疗等方面都具有优势。现有技术中制备聚乙烯醇磁性微球的方法是:先制备磁性材料,再将磁性材料与聚乙烯醇溶液混合均匀后分散到油相中,加入酸(催化剂)和醛(交联剂),在酸催化下,使聚乙烯醇与醛发生羟醛缩合反应制备出聚乙烯醇磁性微球。这种方法存在以下缺陷:一方面,聚乙烯醇的羟醛缩合反应需要在酸催化下进行,而磁性材料(如Fe3O4)会与酸中的氢离子发生反应而失去磁性,从而使制备的聚乙烯醇磁性微球的磁响应性降低;另一方面,酸与磁性物质的反应容易使微球发生粘连,降低了微球的分散性。
发明内容
针对上述问题,本发明的主要目的在于提供一种聚乙烯醇磁性微粒及其制备方法和用途,该聚乙烯醇磁性微粒在制备过程中能够避免磁性材料与酸性催化剂中的氢离子发生反应,从而提高聚乙烯醇磁性微粒的磁响应性及分散性。
为实现上述目的,本发明提供一种聚乙烯醇磁性微粒,该聚乙烯醇磁性微粒通过使聚乙烯醇微粒、磁性金属离子及碱性物质反应制成。
进一步地,所述聚乙烯醇微粒与磁性金属离子的重量比为1:0.005-5;
进一步地,所述聚乙烯醇微粒由反应物原料通过聚合反应制成,所述反应物原料包括:1重量份聚乙烯醇、0-0.09重量份无机盐、0.25-40重量份交联剂及0.01-10重量份催化剂;优选地,所述反应物原料包括:1重量份聚乙烯醇、0.001-0.05重量份无机盐、3.8-18重量份交联剂及0.5-1.1重量份催化剂。
进一步地,所述反应物原料进一步包含0.05-0.6重量份药物。
优选地,所述反应物原料进一步包含表面活性剂及与水不互溶的有机溶剂。
另外,所述聚乙烯醇微粒也可为市售的聚乙烯醇微粒,如市售的聚乙烯醇微球。
进一步地,所述聚乙烯醇微粒及聚乙烯醇磁性微粒可为形状规则的微球或形状不规则的颗粒;优选地,所述聚乙烯醇微粒及聚乙烯醇磁性微粒为粒径为0.1-2000μm的颗粒,优选形状规则的微球。
进一步地,所述磁性金属离子选自铁、锰、镍、钴、钬、钆、铕、铽、镝、铥或镱等离子中的一种或多种,优选两种;
优选地,所述碱性物质选自氢氧化钠、氢氧化钾、氨水、二异丙醇胺、异丙醇胺、四甲基氢氧化铵或氢氧化三甲基乙铵等中的一种或多种;
优选地,所述聚乙烯醇的平均分子量为1,000-500,000D,优选1,000-150,000D;醇解度为50-100%,优选75-100%;
优选地,所述无机盐选自水溶性钠盐、钾盐或铵盐中的一种或多种;优选氯化钾、氯化钠或氯化铵等中的一种或多种;
优选地,所述交联剂选自甲醛、乙醛、乙二醛、丁醛、硼酸、硼砂、戊二醛或己二醛等中的一种或多种;
优选地,所述催化剂选自盐酸、硫酸、磷酸、甲酸或醋酸等中的一种或多种。
进一步地,所述表面活性剂选自司盘类表面活性剂或由司盘类表面活性剂与吐温类表面活性剂组成的混合物中的一种或两种,优选司盘80;
优选地,所述与水不互溶的有机溶剂选自矿物油、植物油、硅油、烯烃、醇、醛、胺、醚、酮、萜烯烃、卤代烃、杂环化物、含氮化合物或含硫化合物等中的一种或多种;优选液体石蜡、蓖麻油、大豆油、正庚烷或环己烷中的一种或多种;
优选地,所述药物选自抗肿瘤药物、局麻药物、解热镇痛抗炎药物或抗生素药物等中的一种或多种;
优选地,所述抗肿瘤药物选自阿霉素、表阿霉素、柔红霉素、丝裂霉素、甲氨喋呤、博来霉素、顺铂、卡铂、伊立替康、紫杉醇、多西紫杉醇、5-氟尿嘧啶、平阳霉素、舒尼替尼(Sunitinib)、索拉非尼(Sorafenib)、吉非替尼(Gefitinib)、伊马替尼(Imatinib)、瓦他拉尼(Vatalanib)或其盐等中的一种或多种;
优选地,所述局麻药物选自普鲁卡因、氯普鲁卡因、羟普鲁卡因、丁卡因、对乙氧卡因、徒托卡因、二甲卡因、利多卡因、三甲卡因、丙胺卡因、甲哌卡因、布比卡因、罗哌卡因、辛可卡因、达克罗宁、法力卡因、奎尼卡因、非那卡因或其盐等中的一种或多种;
优选地,所述解热镇痛抗炎药物选自阿司匹林、水杨酸镁、水杨酸钠、水杨酸胆碱镁、二氟尼柳、双水杨酸酯、布洛芬、吲哚美辛、氟比布洛芬、苯氧基布洛芬、萘普生、萘丁美酮、吡罗昔康、保泰松、对乙酰氨基酚、双氯灭痛、芬洛芬、酮基布洛芬、酮咯酸、四氯芬那酸、舒林酸或托美丁等中的一种或多种;
优选地,所述抗生素药物选自β-内酰胺类抗生素(例如青霉素、苯唑西林钠、氨苄西林钠、阿莫西林、头孢哌酮、头孢噻肟钠、氨曲南、克拉维酸或舒巴坦)、四环素类抗生素(例如土霉素、四环素或地美环素)、氨基糖苷类抗生素(链霉素、卡那霉素A、庆大霉素、妥布霉素、西索米星、阿米卡星、地贝卡星、异帕米星、核糖霉素、卡那霉素B、新霉素B或巴龙霉素)、大环内酯类抗生素(例如红霉素、罗红霉素、克拉霉素或阿奇霉素)或其他抗生素(例如氯霉素、环孢素或林可霉素)或其盐等中的一种或多种。
本发明进一步提供上述聚乙烯醇磁性微粒的制备方法,所述制备方法包括以下步骤:
步骤a:将聚乙烯醇微粒置于含磁性金属离子的溶液中浸泡,并保护溶液中的磁性金属离子不被氧化;
步骤b:在60-100℃和400-2000rpm的搅拌速度下,向步骤a的溶液中加入碱性物质调节pH值至8-14,得到聚乙烯醇磁性微粒。
进一步地,所述聚乙烯醇微粒采用以下方法制备:
步骤a1:称取配方量的聚乙烯醇并配制成0.005-0.4g/ml,优选0.1-0.25g/ml,更优选0.22g/ml的聚乙烯醇溶液,加入无机盐及可选的药物,搅拌均匀;
步骤a2:在10-80℃优选15-75℃的水浴温度和200-1600rpm优选300-1400rpm,更优选600rpm的搅拌速度下,将步骤a1得到的混合液倒入含表面活性剂的与水不互溶的有机溶剂中,再加入交联剂和催化剂,反应1-24h,优选4h,过滤、洗涤后得到聚乙烯醇微粒;或
所述聚乙烯醇微粒采用以下方法制备:
步骤a3:称取配方量的聚乙烯醇并配制成0.005-0.4g/ml,优选0.1-0.25g/ml,更优选0.22g/ml的聚乙烯醇溶液,加入无机盐及可选的药物,搅拌均匀;
步骤a4:在步骤a3得到的溶液中加入交联剂和催化剂,迅速搅拌均匀后倒入含表面活性剂的与水不互溶的有机溶剂中,在10-80℃优选15-75℃的水浴温度下,以200-1600rpm优选300-1400rpm,更优选600rpm的速度搅拌1-24h,优选4h,过滤、洗涤后得到聚乙烯醇微粒。
进一步地,所述步骤a中,将聚乙烯醇微粒置于含磁性金属离子的溶液中浸泡10min以上,优选30-120min,并采用通入保护气体或抽真空的方法保护溶液中的磁性金属离子不被氧化;
优选地,所述保护气体选自氮气或惰性气体等中的一种或多种;
优选地,所述步骤b中,在60-100℃和400-2000rpm的搅拌速度下,向步骤a的混合液中加入碱性物质,调节pH值至8-14,反应时间大于5min,优选20-180min,得到聚乙烯醇磁性微粒。
本发明进一步提供上述聚乙烯醇磁性微粒在制备用于介入栓塞治疗、热疗、磁靶向性治疗或细胞分离的药物中的用途。
本发明的聚乙烯醇磁性微粒可用于栓塞治疗中。现有的栓塞材料通常不能被磁共振成像(magnetic resonance imaging,MRI)所检测,因此在栓塞术中和术后都不能对栓塞材料所处的位置进行直接检测。现有技术中通常通过数字减影血管造影术(digital subtraction angiography,DSA)检查造影剂的流动而间接判断栓塞材料的位置和栓塞终点,研究表明这种间接判断并不能代表真实结果。而采用本发明的聚乙烯醇磁性微粒作为介入栓塞治疗的栓塞剂时,除了作为栓塞材料满足介入栓塞治疗的要求(通常选取粒径为100-2000μm的微粒,可筛分成一定粒径范围如:100-300μm、300-500μm、500-700μm等使用)外,还能够被MRI直接检测,从而能够准确判断栓塞材料的位置和栓塞终点,提高了栓塞治疗的疗效和安全性。
本发明的聚乙烯醇磁性微粒可用于热疗。热疗时先使聚乙烯醇磁性微粒聚集到病灶部位,如通过栓塞到病灶血管、局部注射、外加磁场、植入内部诱导磁场到病灶部位等,然后外加交变电磁场,使聚乙烯醇磁性微粒中的磁性物质在交变电磁场的作用下吸收电磁能,产生热量,形成巨大的储热库,从而杀伤病灶部位的肿瘤细胞。
本发明的聚乙烯醇磁性微粒可用于磁靶向性治疗。治疗时,可将本发明制备的载药聚乙烯醇磁性微粒通过各种方式给药,如:口服、静脉注射、动脉注射或局部注射等,然后在外加磁场等的引导下,定位于病灶部位(即靶向到病灶),使药物在病灶部位缓慢释放,从而提高局部的治疗浓度,延长药物作用时间并降低全身毒副作用。
与现有技术相比,本发明制备的聚乙烯醇磁性微粒至少具有以下优点:
1、本发明的聚乙烯醇磁性微粒的制备方法避免了磁性材料和酸性催化剂中的氢离子发生反应,从而提高了聚乙烯醇磁性微粒的磁响应性,减少了微粒间的粘连和聚集。
2、本发明的聚乙烯醇磁性微粒的制备方法工艺简单,成本低,适合大规模的工业化生产,有利于产品的临床推广应用。
3、本发明的聚乙烯醇磁性微粒用于栓塞治疗时,一方面医生能够通过MRI直接监测栓塞剂所在的位置,便于及时采取措施避免异位栓塞和返流;另一方面,医生能够通过MRI检测栓塞剂在血管内的填充情况,对被填塞血管的长度、栓塞是否致密及栓塞血管的走向等做出准确判断,便于医生准确地判断栓塞终点,因此,能够提高栓塞治疗的疗效和安全性。
4、本发明的聚乙烯醇磁性微粒用于栓塞治疗时,在栓塞治疗后,医生能够通过MRI检测栓塞剂在体内的分布情况,包括栓塞剂在血管内的分布是否均匀、栓塞剂的分布是否发生变化等,有利于评估栓塞效果,并为进一步治疗提供有益的信息。
5、本发明的聚乙烯醇磁性微粒使医生能够利用MRI进行栓塞的治疗研究:栓塞后微粒在体内的三维分布,应用不同剂量、不同浓度时微粒所达到的位置和疗效都可以被MRI直接检测,有利于医生不断改进栓塞技术,从而有利于提高栓塞治疗的疗效与安全性。
6、本发明的聚乙烯醇磁性微粒,在栓塞治疗的术中和术后均能够在MRI下进行检测,可以避免X射线检查对患者造成的辐射性损伤。
7、本发明的聚乙烯醇磁性微粒用于热疗时,聚乙烯醇磁性微粒可通过各种方式被聚集在病灶部位,在外加交变电磁场的作用下,聚乙烯醇磁性微粒中的磁性物质能够吸收电磁能,产生热量,形成巨大的储热库,杀伤肿瘤细胞而不损伤正常细胞,从而避免了放疗、化疗等引起的诸如骨髓抑制、脱发等不良反应。
8、本发明的载药聚乙烯醇磁性微粒用于靶向性治疗时,载药聚乙烯醇磁性微粒可以在外加磁场的引导下,定向移动并被定位集中于病灶部位,使药物在病灶部位缓慢释放,从而提高了局部的治疗浓度,延长了药物作用时间,并降低了全身毒副作用,使治疗的靶向性和专一性更强,治疗更加准确快速。
附图说明
以下,结合附图来详细说明本发明的实施方案,其中:
图1为本发明实施例2制备的聚乙烯醇微球的光学显微镜照片;
图2为本发明实施例2制备的聚乙烯醇微球的磁响应性检测照片;
图3为本发明实施例2制备的聚乙烯醇磁性微球的光学显微镜照片;
图4为本发明实施例2制备的聚乙烯醇磁性微球的磁响应性检测照片;
图5为本发明实施例2制备的聚乙烯醇磁性微球的MRI体外检测图像;
图6为本发明实施例2制备的聚乙烯醇磁性微球在小鼠皮下的MRI图像;
图7为根据现有技术制备的聚乙烯醇磁性微球的光学显微镜照片。
具体实施方式
以下参照具体的实施例来说明本发明。本领域技术人员能够理解,这些实施例仅用于说明本发明,其不以任何方式限制本发明的范围。
下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的药物原料、试剂、材料等,如无特殊说明,均为市售购买产品。
实施例1:聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.23g/ml的聚乙烯醇溶液,将0.05g氯化钾加入到聚乙烯醇溶液中,搅拌均匀;
(2)在25℃的水浴温度和1600rpm的搅拌速度下,将步骤(1)得到的溶液倒入含司盘85的蓖麻油中,再加入4.3g戊二醛和1.1g盐酸,反应3h,过滤、洗涤后得到聚乙烯醇微球;
(3)将上述制备的聚乙烯醇微球浸泡在含0.17g三价铁离子和0.08g二价锰离子的溶液中,向溶液中通入氮气,浸泡60min;
(4)在100℃和700rpm搅拌条件下,向步骤(3)的混合液中加入3mol/L异丙醇胺溶液调节pH值至8-14,反应180min,得到聚乙烯醇磁性微球。
实施例2:聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.22g/ml的聚乙烯醇溶液;
(2)在步骤(1)得到的溶液中加入2.6g甲醛和1g硫酸,迅速搅拌均匀后倒入含司盘80的液体石蜡中,在25℃的水浴温度下,以600rpm的速度搅拌4h,过滤、洗涤后得到聚乙烯醇微球;
制备的聚乙烯醇微球在光学显微镜下的形态如图1所示,从图1中看出制备的聚乙烯醇微球为规则的球形,分散性较好,无粘结和团聚现象;
另外将制备的聚乙烯醇微球置于西林瓶中,用磁铁靠近西林瓶时,聚乙烯醇微球在磁场作用下不会向磁铁聚集,微球的磁响应性检测如图2所示;
(3)将上述制备的聚乙烯醇微球浸泡在含0.34g三价铁离子和0.16二价铁离子的溶液中,向溶液中通入氮气,浸泡120min;
(4)在60℃和800rpm搅拌条件下,向步骤(3)的混合液中加入8mol/L的氢氧化钠溶液调节pH值至8-14,反应60min,得到聚乙烯醇磁性微球。
上述制备的聚乙烯醇磁性微球在光学显微镜下的形态如图3所示。从图3看出,制备的聚乙烯醇磁性微球为规则的球形,分散性较好,无粘结和团聚现象。
另外将制备的聚乙烯醇磁性微球置于西林瓶中,用磁铁靠近西林瓶时,聚乙烯醇磁性微球在磁场作用下向磁铁聚集,聚乙烯醇磁性微球的磁响应性检测如图4所示。
实施例3:聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.1g/ml的聚乙烯醇溶液,将0.09g氯化铵加入到聚乙烯醇溶液中,搅拌均匀;
(2)在步骤(1)得到的溶液中加入18g甲醛和4g硫酸,迅速搅拌均匀后倒入含司盘80的液体石蜡中,在15℃的水浴温度下,以1400rpm的速度搅拌24h,过滤、洗涤后得到聚乙烯醇微球;
(3)将上述制备的聚乙烯醇微球浸泡在含0.21g三价铁离子和0.12g二价铁离子的溶液中,在溶液中通入氮气,浸泡60min;
(4)在75℃和900rpm搅拌条件下,向步骤(3)的混合液中加入10mol/L的氢氧化钾溶液调节pH值至8-14,反应45min,得到聚乙烯醇磁性微球。
实施例4:聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.22g/ml的聚乙烯醇溶液,将0.05g氯化钠加入到聚乙烯醇溶液中,搅拌均匀;
(2)在50℃的水浴温度和600rpm的搅拌速度下,将步骤(1)得到的溶液倒入含司盘80的大豆油中,再加入3.8g乙醛和1g醋酸,反应4h,过滤、洗涤后得到聚乙烯醇微球;
(3)将上述制备的聚乙烯醇微球浸泡在0.68g三价铁离子和0.32g二价镍离子的溶液中,在溶液中通入氮气,浸泡100min;
(4)在80℃和700rpm搅拌条件下,向步骤(3)的混合液中加入25%w/w的氨水溶液调节pH值至8-14,反应30min,得到聚乙烯醇磁性微球。
实施例5:载药聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.21g/ml的聚乙烯醇溶液,将0.02g氯化钠和0.05g索拉非尼加入到聚乙烯醇溶液中,搅拌均匀;
(2)在步骤(1)得到的混合液中加入15g甲醛和4g盐酸,迅速搅拌均匀后倒入含司盘80的正庚烷中,在25℃的水浴温度下,以600rpm的速度搅拌2.5h,过滤、洗涤后得到载索拉非尼的聚乙烯醇微球;
(3)将上述制备的载索拉非尼的聚乙烯醇微球浸泡在0.14g三价铁离子和0.08g二价钴离子的溶液中,在溶液中通入氮气,浸泡120min;
(4)在100℃和700rpm搅拌条件下,向步骤(3)的混合液中加入3mol/L的二异丙醇胺溶液调节pH值至8-14,反应120min,得到载药聚乙烯醇磁性微球。
实施例6:聚乙烯醇磁性微球的制备
(1)称取1g市售的聚乙烯醇微粒,将其浸泡在含0.51g三价铁离子和0.24g二价锰离子的溶液中,向溶液中通入氮气,浸泡100min;
(2)在70℃和1000rpm搅拌条件下,向步骤(1)的混合液中加入10mol/L氢氧化钠溶液调节pH值至8-14,反应60min,得到聚乙烯醇磁性微球。
实施例7:聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.1g/ml的聚乙烯醇溶液;
(2)在50℃的水浴温度和200rpm的搅拌速度下,将步骤(1)得到的溶液倒入含司盘80的液体石蜡中,再加入30g戊二醛和7g盐酸,反应3h,过滤、洗涤后得到聚乙烯醇微球;
(3)将上述制备的聚乙烯醇微球浸泡在含0.29g三价铁离子和0.16g二价铁离子的溶液中,向溶液中通入氮气,浸泡30min;
(4)在80℃和700rpm搅拌条件下,向步骤(3)的混合液中加入10mol/L氢氧化钾溶液调节pH值至8-14,反应60min,得到聚乙烯醇磁性微球。
实施例8:聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.4g/ml的聚乙烯醇溶液,将0.001g氯化钠加入到聚乙烯醇溶液中,搅拌均匀;
(2)在75℃的水浴温度和1500rpm的搅拌速度下,将步骤(1)得到的溶液倒入含司盘80的液体石蜡中,再加入0.25g甲醛和0.01g盐酸,反应4h,过滤、洗涤后得到聚乙烯醇微球;
(3)将上述制备的聚乙烯醇微球浸泡在1.5g三价铁离子和0.64g二价铁离子的溶液中,向溶液中通入氮气,浸泡60min;
(4)在80℃和700rpm搅拌条件下,向步骤(3)的混合液中加入25%w/w氨水溶液调节pH值至8-14,反应180min,得到聚乙烯醇磁性微球。
实施例9:载药聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.25g/ml的聚乙烯醇溶液,将0.01g氯化钾和0.6g紫杉醇加入到聚乙烯醇溶液中,搅拌均匀;
(2)在步骤(1)得到的混合液中加入2.8g甲醛和0.5g硫酸,迅速搅拌均匀后倒入含司盘80的液体石蜡中,在80℃的水浴温度下,以300rpm的速度搅拌1h,过滤、洗涤后得到载紫杉醇的聚乙烯醇微球;
(3)将上述制备的载紫杉醇的聚乙烯醇微球浸泡在3.4g三价铁离子和1.6g二价锰离子的溶液中,在溶液中通入氮气,浸泡120min;
(4)在60℃和400rpm搅拌条件下,向步骤(3)的混合液中加入10mol/L的氢氧化钠溶液调节pH值至8-14,反应120min,得到载药聚乙烯醇磁性微球。
实施例10:载药聚乙烯醇磁性微球的制备
(1)称取1g聚乙烯醇,配制成0.005g/ml的聚乙烯醇溶液,将0.2g顺铂加入到聚乙烯醇溶液中,搅拌均匀;
(2)在步骤(1)得到的混合液中加入40g戊二醛和10g盐酸,迅速搅拌均匀后倒入含司盘80的大豆油中,在10℃的水浴温度下,以400rpm的速度搅拌23h,过滤、洗涤后得到载顺铂的聚乙烯醇微球;
(3)将上述制备的载顺铂的聚乙烯醇微球浸泡在0.0032g三价铁离子和0.0018g二价铁离子的溶液中,在溶液中通入氮气,浸泡60min;
(4)在60℃和2000rpm搅拌条件下,向步骤(3)的混合液中加入3mol/L的异丙醇胺溶液调节pH值至8-14,反应20min,得到载药聚乙烯醇磁性微球。
对比例:采用现有技术制备聚乙烯醇磁性微球
根据现有技术制备聚乙烯醇磁性微球,其中各物质的含量及工艺条件与实施例2相同。
(1)向含0.34g三价铁离子和0.16g二价铁离子的溶液中通入氮气,在60℃和800rpm搅拌条件下,加入8mol/L的氢氧化钠溶液调节溶液的pH值至8-14,反应60min,用去离子水洗涤沉淀,制得磁流体;
(2)称取1g聚乙烯醇,配制成0.22g/ml的聚乙烯醇溶液,将步骤(1)中制得的磁流体加入到聚乙烯醇溶液中,搅拌均匀;
(3)在步骤(2)得到的溶液中加入2.6g甲醛和1g硫酸,迅速搅拌均匀后倒入含司盘80的液体石蜡中,在温度25℃的水浴温度下,以600rpm的速度搅拌4h,过滤、洗涤后得到聚乙烯醇磁性微球。
聚乙烯醇磁性微粒的体外MRI检测
配制2%琼脂热溶液,倒入培养皿中,使液面厚度为1.5cm,待溶液冷却形成凝胶后,将实施例2制备的聚乙烯醇微球和聚乙烯醇磁性微球分别放在琼脂表面,再次倒入厚度为1cm的琼脂热溶液并冷却。将表面皿置于3T MRI下进行扫描,检测结果如图5所示。图5中示出了聚乙烯醇磁性微球(右侧,黑色)与聚乙烯醇微球(左侧,白色)的体外MRI检测结果(从上至下两侧微球的数目分别为1、2、3、4、5、6个),从图5中看出,在MRI下,聚乙烯醇磁性微球清晰可见,而聚乙烯醇微球基本未被检测到。
聚乙烯醇磁性微粒在小鼠皮下的MRI检测
从实施例2制备的聚乙烯醇磁性微球中筛分出100-300μm的微球,将2.5ml微球混悬到20ml含1%羧甲基纤维素钠的生理盐水中,取0.15ml注入小鼠皮下。将小鼠置于3T MRI下进行扫描,检测结果如图6所示。图6示出了聚乙烯醇磁性微球在小鼠皮下的MRI图像(其中小鼠体外的白色亮点为维生素E胶囊(用于标识注射部位),白色箭头所指为聚乙烯醇磁性微球的注射部位),从图6中看出,通过MRI可在小鼠皮下注射部位检出聚乙烯醇磁性微球。
聚乙烯醇磁性微球体内栓塞
从实施例2制得的聚乙烯醇磁性微球中筛分出粒径为100-150μm的微球,灭菌后备用。将禁食12小时的家兔麻醉后固定于手术台上,分离一侧颈动脉,在数字减影血管造影(DSA)下,经颈动脉用2.8F导管和导丝进行选择性左肾动脉插管,注入0.15ml微球进行肾栓塞,栓塞前后均对左肾进行DSA检查以确定靶血管是否闭塞。术后进行MRI检测,检测结果显示微球所在的位置与DSA检查结果一致。
聚乙烯醇磁性微球用于热疗
从实施例2制得的聚乙烯醇磁性微球中筛分出粒径为20-50μm的微球,灭菌后备用。将VX-2肿瘤细胞移植到兔子肝脏中,移植成功后将6只荷瘤兔随机分为实验组和对照组,麻醉后,两组分别从肝动脉注射相同量的聚乙烯醇磁性微球。仅在实验组肿瘤外部加高频交变磁场进行热疗。结果显示,与对照组相比,实验组的热疗可以完全消除肿瘤,MRI和组织学检查均能监测到肝脏部位磁性微球的聚集。
聚乙烯醇磁性微球的磁靶向性检测
从实施例2制得的聚乙烯醇磁性微球中筛分出粒径为0.5-0.8μm的微球,灭菌后备用。选6只健康新西兰大白兔,随机分为实验组(右肾部位加磁场)和对照组(不加磁场),麻醉后,两组分别从股动脉注射相同量的聚乙烯醇磁性微球。实验组注射完毕后磁场继续作用1h,移去磁体,0.5h后进行右肾部位MRI检查;对照组注射完毕1.5h后进行右肾部位MRI检查。MRI结果显示,磁性微球在实验组兔子右肾部位的聚集度远高于对照组,说明在靶部位加磁场可以大大提高磁性微球在靶部位的聚集。
聚乙烯醇磁性微球的磁靶向性治疗
从实施例5制得的载索拉非尼聚乙烯醇磁性微球中筛分出粒径为0.1-0.2μm的微球,灭菌后备用。选新西兰大白兔,建立VX2肝肿瘤模型,将20只荷瘤兔随机分为实验组和对照组,每组10只。实验组动物进行栓塞治疗后,在肿瘤部位加磁场30min,对照组仅栓塞不加磁场。术前1天和术后14天分别对动物进行CT扫描检查肿瘤大小,并在术后14天CT检查后处死动物,检查肝内肿瘤大小,及腹部、肺部等的转移情况。结果显示实验组抑瘤率明显高于对照组,肿瘤转移率明显低于对照组。说明载索拉非尼聚乙烯醇磁性微球的磁响应性良好,磁靶向性治疗效果显著。
测试1:磁响应性检测
取相同量对比例(现有技术)和本发明实施例2制备的聚乙烯醇磁性微球分别置于西林瓶中,用磁铁靠近西林瓶来检测两种方法制备的聚乙烯醇磁性微球的磁响应性。实验表明,相对于现有技术制备的聚乙烯醇磁性微球,采用本发明方法制备的聚乙烯醇磁性微球能够较快速地、完全地聚集在磁铁侧,说明本发明的聚乙烯醇磁性微球具有较强的磁响应性。
测试2:分散性检测
取对比例(现有技术)和本发明实施例2制备的聚乙烯醇磁性微球分别置于光学显微镜下观察。显微镜图片显示,采用现有技术制备的聚乙烯醇磁性微球严重粘连,几乎看不到单分散的微球(如图7所示);而采用本发明方法制备的聚乙烯醇磁性微球呈规整的球形,分散性良好,无粘结和团聚现象(参见图3)。
以上对本发明具体实施方式的描述并不限制本发明,本领域技术人员可以根据本发明作出各种改变或变形,只要不脱离本发明的精神,均应属于本发明所附权利要求的范围。
Claims (11)
1.一种聚乙烯醇磁性微粒,其通过使聚乙烯醇微粒、磁性金属离子及碱性物质反应制成。
2.根据权利要求1所述的聚乙烯醇磁性微粒,其特征在于,所述聚乙烯醇微粒与磁性金属离子的重量比为1:0.005-5。
3.根据权利要求1或2所述的聚乙烯醇磁性微粒,其特征在于,所述聚乙烯醇微粒由反应物原料通过聚合反应制成,所述反应物原料包括:1重量份聚乙烯醇、0-0.09重量份无机盐、0.25-40重量份交联剂及0.01-10重量份催化剂;
优选地,所述反应物原料包括:1重量份聚乙烯醇、0.001-0.05重量份无机盐、3.8-18重量份交联剂及0.5-1.1重量份催化剂。
4.根据权利要求3所述的聚乙烯醇磁性微粒,其特征在于,所述反应物原料进一步包含0.05-0.6重量份药物;
优选地,所述反应物原料进一步包含表面活性剂及与水不互溶的有机溶剂。
5.根据权利要求1至4中任一项所述的聚乙烯醇磁性微粒,其特征在于,所述聚乙烯醇微粒及聚乙烯醇磁性微粒为粒径为0.1-2000μm的颗粒,优选形状规则的微球。
6.根据权利要求1至5中任一项所述的聚乙烯醇磁性微粒,其特征在于,所述磁性金属离子选自铁、锰、镍、钴、钬、钆、铕、铽、镝、铥或镱离子中的一种或多种,优选两种;
优选地,所述碱性物质选自氢氧化钠、氢氧化钾、氨水、二异丙醇胺、异丙醇胺、四甲基氢氧化铵或氢氧化三甲基乙铵中的一种或多种;
优选地,所述聚乙烯醇的平均分子量为1,000-500,000D,优选1,000-150,000D;醇解度为50-100%,优选75-100%;
优选地,所述无机盐选自水溶性钠盐、钾盐或铵盐中的一种或多种;优选氯化钾、氯化钠或氯化铵中的一种或多种;
优选地,所述交联剂选自甲醛、乙醛、乙二醛、丁醛、硼酸、硼砂、戊二醛或己二醛中的一种或多种;
优选地,所述催化剂选自盐酸、硫酸、磷酸、甲酸或醋酸中的一种或多种。
7.根据权利要求4至6中任一项所述的聚乙烯醇磁性微粒,其特征在于,所述表面活性剂选自司盘类表面活性剂或由司盘类表面活性剂与吐温类表面活性剂组成的混合物中的一种或两种,优选司盘80;
优选地,所述与水不互溶的有机溶剂选自矿物油、植物油、硅油、烯烃、醇、醛、胺、醚或酮中的一种或多种;优选液体石蜡、蓖麻油、大豆油、正庚烷或环己烷中的一种或多种;
优选地,所述药物选自抗肿瘤药物、局麻药物、解热镇痛抗炎药物或抗生素药物中的一种或多种;
优选地,所述抗肿瘤药物选自阿霉素、表阿霉素、柔红霉素、丝裂霉素、甲氨喋呤、博来霉素、顺铂、卡铂、伊立替康、紫杉醇、多西紫杉醇、5-氟尿嘧啶、平阳霉素、舒尼替尼、索拉非尼、吉非替尼、伊马替尼、瓦他拉尼或其盐中的一种或多种;
优选地,所述局麻药物选自普鲁卡因、氯普鲁卡因、羟普鲁卡因、丁卡因、对乙氧卡因、徒托卡因、二甲卡因、利多卡因、三甲卡因、丙胺卡因、甲哌卡因、布比卡因、罗哌卡因、辛可卡因、达克罗宁、法力卡因、奎尼卡因、非那卡因或其盐中的一种或多种;
优选地,所述解热镇痛抗炎药物选自阿司匹林、水杨酸镁、水杨酸钠、水杨酸胆碱镁、二氟尼柳、双水杨酸酯、布洛芬、吲哚美辛、氟比布洛芬、苯氧基布洛芬、萘普生、萘丁美酮、吡罗昔康、保泰松、对乙酰氨基酚、双氯灭痛、芬洛芬、酮基布洛芬、酮咯酸、四氯芬那酸、舒林酸或托美丁中的一种或多种;
优选地,所述抗生素药物选自青霉素、苯唑西林钠、氨苄西林钠、阿莫西林、头孢哌酮、头孢噻肟钠、氨曲南、克拉维酸、舒巴坦、土霉素、四环素、地美环素、链霉素、卡那霉素A、庆大霉素、妥布霉素、西索米星、阿米卡星、地贝卡星、异帕米星、核糖霉素、卡那霉素B、新霉素B、巴龙霉素、红霉素、罗红霉素、克拉霉素、阿奇霉素、氯霉素、环孢素、林可霉素或其盐中的一种或多种。
8.根据权利要求1至7中任一项所述的聚乙烯醇磁性微粒的制备方法,所述制备方法包括以下步骤:
步骤a:将聚乙烯醇微粒置于含磁性金属离子的溶液中浸泡,并保护溶液中的磁性金属离子不被氧化;
步骤b:在60-100℃和400-2000rpm的搅拌速度下,向步骤a的混合液中加入碱性物质调节pH值至8-14,得到聚乙烯醇磁性微粒。
9.根据权利要求8所述的制备方法,其特征在于,所述聚乙烯醇微粒采用以下方法制备:
步骤a1:称取配方量的聚乙烯醇并配制成0.005-0.4g/ml,优选0.1-0.25g/ml,更优选0.22g/ml的聚乙烯醇溶液,加入无机盐及可选的药物,搅拌均匀;
步骤a2:在10-80℃优选15-75℃的水浴温度和200-1600rpm优选300-1400rpm,更优选600rpm的搅拌速度下,将步骤a1得到的溶液倒入含表面活性剂的与水不互溶的有机溶剂中,再加入交联剂和催化剂,反应1-24h,优选4h,过滤、洗涤后得到聚乙烯醇微粒;或
所述聚乙烯醇微粒采用以下方法制备:
步骤a3:称取配方量的聚乙烯醇并配制成0.005-0.4g/ml,优选0.1-0.25g/ml,更优选0.22g/ml的聚乙烯醇溶液,加入无机盐及可选的药物,搅拌均匀;
步骤a4:在步骤a3得到的溶液中加入交联剂和催化剂,迅速搅拌均匀后倒入含表面活性剂的与水不互溶的有机溶剂中,在10-80℃优选15-75℃的水浴温度下,以200-1600rpm优选300-1400rpm,更优选600rpm的速度搅拌1-24h,优选4h,过滤、洗涤后得到聚乙烯醇微粒。
10.根据权利要求8或9所述的制备方法,其特征在于,所述步骤a中,将聚乙烯醇微粒置于含磁性金属离子的溶液中浸泡10min以上,优选30-120min,并采用通入保护气体或抽真空的方法保护溶液中的磁性金属离子不被氧化;
优选地,所述保护气体选自氮气或惰性气体中的一种或多种;
优选地,所述步骤b中,在60-100℃和400-2000rpm的搅拌速度下,向步骤a的混合液中加入碱性物质,调节pH值至8-14,反应时间大于5min,优选20-180min,得到聚乙烯醇磁性微粒。
11.根据权利要求1至7中任一项所述的聚乙烯醇磁性微粒在制备用于介入栓塞治疗、热疗、磁靶向性治疗或细胞分离的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310513211.0A CN103536973B (zh) | 2013-10-25 | 2013-10-25 | 一种聚乙烯醇磁性微粒及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310513211.0A CN103536973B (zh) | 2013-10-25 | 2013-10-25 | 一种聚乙烯醇磁性微粒及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103536973A true CN103536973A (zh) | 2014-01-29 |
CN103536973B CN103536973B (zh) | 2015-10-28 |
Family
ID=49961075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310513211.0A Active CN103536973B (zh) | 2013-10-25 | 2013-10-25 | 一种聚乙烯醇磁性微粒及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103536973B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104857576A (zh) * | 2015-04-24 | 2015-08-26 | 山东省科学院能源研究所 | 一种同步固化制备聚乙烯醇栓塞微球的方法 |
CN105462915A (zh) * | 2016-01-28 | 2016-04-06 | 北京爱美客生物科技有限公司 | 聚乙烯醇微载体及其制备方法与应用 |
CN106214489A (zh) * | 2016-09-09 | 2016-12-14 | 山东省科学院能源研究所 | 一种双层乳化液滴、载药微球及其制备方法和装置 |
CN107338238A (zh) * | 2017-07-31 | 2017-11-10 | 苏州凯邦生物技术有限公司 | 一种固定化漆酶及其制备方法 |
CN109293859A (zh) * | 2018-10-15 | 2019-02-01 | 西安交通大学 | 一种亲水性舒林酸分子印迹磁性纳米树脂球及其制备方法和应用 |
CN111097522A (zh) * | 2019-12-31 | 2020-05-05 | 江南大学 | 一种可控缓释催化剂的制备方法 |
CN113307276A (zh) * | 2021-05-13 | 2021-08-27 | 江苏理文化工有限公司 | 一种sba-15微球的制备方法 |
CN116173284A (zh) * | 2017-07-13 | 2023-05-30 | 瓦里安医疗系统公司 | 栓塞微球 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541712A (zh) * | 2003-11-04 | 2004-11-03 | 上海大学 | Fe3O4磁流体及其制备方法 |
US20080248086A1 (en) * | 2007-04-05 | 2008-10-09 | Cinvention Ag | Curable therapeutic implant composition |
CN102502877A (zh) * | 2011-10-18 | 2012-06-20 | 南开大学 | 一种简单合成多孔四氧化三铁磁性微球的方法 |
-
2013
- 2013-10-25 CN CN201310513211.0A patent/CN103536973B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541712A (zh) * | 2003-11-04 | 2004-11-03 | 上海大学 | Fe3O4磁流体及其制备方法 |
US20080248086A1 (en) * | 2007-04-05 | 2008-10-09 | Cinvention Ag | Curable therapeutic implant composition |
CN102502877A (zh) * | 2011-10-18 | 2012-06-20 | 南开大学 | 一种简单合成多孔四氧化三铁磁性微球的方法 |
Non-Patent Citations (3)
Title |
---|
SOPHIE LAURENT ET AL.: "Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization,Physicochemical Characterizations, and Biological Applications", 《CHEM. REV.》, vol. 108, 6 November 2008 (2008-11-06), pages 2064 - 2110, XP055158397, DOI: 10.1021/cr068445e * |
孟凡卓等: "磁性聚乙烯醇微球的制备及表征", 《化学研究与应用》, vol. 20, no. 6, 30 June 2008 (2008-06-30), pages 710 - 713 * |
臧姝等: "磁性聚乙烯醇微球的制备及其性质", 《材料导报》, vol. 21, 31 May 2007 (2007-05-31) * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104857576A (zh) * | 2015-04-24 | 2015-08-26 | 山东省科学院能源研究所 | 一种同步固化制备聚乙烯醇栓塞微球的方法 |
CN105462915A (zh) * | 2016-01-28 | 2016-04-06 | 北京爱美客生物科技有限公司 | 聚乙烯醇微载体及其制备方法与应用 |
CN105462915B (zh) * | 2016-01-28 | 2018-10-16 | 爱美客技术发展股份有限公司 | 聚乙烯醇微载体及其制备方法与应用 |
CN106214489A (zh) * | 2016-09-09 | 2016-12-14 | 山东省科学院能源研究所 | 一种双层乳化液滴、载药微球及其制备方法和装置 |
CN116173284A (zh) * | 2017-07-13 | 2023-05-30 | 瓦里安医疗系统公司 | 栓塞微球 |
CN107338238A (zh) * | 2017-07-31 | 2017-11-10 | 苏州凯邦生物技术有限公司 | 一种固定化漆酶及其制备方法 |
CN107338238B (zh) * | 2017-07-31 | 2020-09-04 | 苏州凯邦生物技术有限公司 | 一种固定化漆酶及其制备方法 |
CN109293859A (zh) * | 2018-10-15 | 2019-02-01 | 西安交通大学 | 一种亲水性舒林酸分子印迹磁性纳米树脂球及其制备方法和应用 |
CN111097522A (zh) * | 2019-12-31 | 2020-05-05 | 江南大学 | 一种可控缓释催化剂的制备方法 |
CN111097522B (zh) * | 2019-12-31 | 2023-09-01 | 江南大学 | 一种可控缓释催化剂的制备方法 |
CN113307276A (zh) * | 2021-05-13 | 2021-08-27 | 江苏理文化工有限公司 | 一种sba-15微球的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103536973B (zh) | 2015-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103536973B (zh) | 一种聚乙烯醇磁性微粒及其制备方法和用途 | |
CN103550834B (zh) | 一种栓塞材料组合物及其制备方法和用途 | |
Meng et al. | Near-infrared-triggered in situ gelation system for repeatedly enhanced photothermal brachytherapy with a single dose | |
Wang et al. | Injectable 2D MoS2‐integrated drug delivering implant for highly efficient NIR‐triggered synergistic tumor hyperthermia | |
Liu et al. | Water‐responsive hybrid nanoparticles codelivering ICG and DOX effectively treat breast cancer via hyperthermia‐aided DOX functionality and drug penetration | |
CN103550832B (zh) | 一种栓塞材料及其制备方法和用途 | |
Agerholm-Larsen et al. | Preclinical validation of electrochemotherapy as an effective treatment for brain tumors | |
CN102988274B (zh) | 用于治疗肿瘤的药物缓释血管栓塞凝胶剂及其制备方法 | |
CN102711776B (zh) | 用于与放射疗法组合治疗癌症的颗粒 | |
Liang et al. | High-performance poly (lactic-co-glycolic acid)-magnetic microspheres prepared by rotating membrane emulsification for transcatheter arterial embolization and magnetic ablation in VX2 liver tumors | |
JP2008513381A (ja) | パクリタキセル−アルギン酸ナトリウムマイクロスフェア血管塞栓剤及びその製造方法 | |
CN103536970B (zh) | 一种栓塞材料及其制备方法和用途 | |
Xuan et al. | Bismuth particles imbedded degradable nanohydrogel prepared by one-step method for tumor dual-mode imaging and chemo-photothermal combined therapy | |
CN107715169B (zh) | 含plga纳米微粒的海藻酸钠载药复合栓塞微球的制备方法及产品 | |
Wang et al. | Facile and controllable synthesis of the renal-clearable “luminous pearls” for in vivo afterglow/magnetic resonance imaging | |
ITRM980303A1 (it) | Composizione contenente radioisotopi immobilizzati su particelle solide utile in particolare per la biancheria clinica in patologie | |
CN101940797B (zh) | 一种包壳的核素标记蛋白微球及其制备方法和用途 | |
Zhu et al. | Liquid metal‐enabled microspheres with high drug loading and multimodal imaging for artery embolization | |
Luo et al. | Near-Infrared Persistent Luminescence Nanoprobe for Early Detection of Atherosclerotic Plaque | |
Zhang et al. | ZIF-based carbon dots with lysosome-Golgi transport property as visualization platform for deep tumour therapy via hierarchical size/charge dual-transform and transcytosis | |
CN103446061A (zh) | 可显影纳米银海藻酸钠微球血管栓塞剂及其制备方法 | |
CN103751856A (zh) | 一种具有良好分散性的聚乳酸类栓塞微球 | |
CN1783363A (zh) | 四氧化三铁磁流体及其制备方法和应用 | |
Chen et al. | Dual-modality imaging particle size monodisperse poly (ethylene glycol) diacrylate drug-loaded embolic microspheres for tumor therapy | |
CN105283202B (zh) | 用于淋巴结检测的低渗溶液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211224 Address after: 100083 Room 606, 6th floor, building 9, 35 Huayuan North Road, Haidian District, Beijing Patentee after: HYGEA MEDICAL TECHNOLOGY Co.,Ltd. Address before: 100191 Department of pharmacy, Department of medicine, Peking University, No. 38 Xueyuan Road, Haidian District, Beijing Patentee before: Peking University |
|
TR01 | Transfer of patent right |